Case report: Salvage capmatinib therapy in KIF5B-MET fusion-positive lung adenocarcinoma with resistance to telisotuzumab vedotin

Case report: Salvage capmatinib therapy in KIF5B-MET fusion-positive lung adenocarcinoma with resistance to telisotuzumab vedotin

Telisotuzumab vedotin is a MET-targeting antibody–drug conjugate that has demonstrated a good treatment response in patients with EGFR wild-type MET-overexpressing non-squamous non-small cell lung cancer. However, patients have been reported to acquire resistance to this drug, and the subsequent the...

Full description

Bibliographic Details
Main Authors: Chien-Yu Lin, Sheng-Huan Wei, Yi-Lin Chen, Chung-Ta Lee, Shang-Yin Wu, Chung-Liang Ho, Dean C. Pavlick, Po-Lan Su, Chien-Chung Lin
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Oncology
Subjects:
KIF5B-MET fusion
lung adenocarcinoma
capmatinib
telisotuzumab vedotin
case report
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.919123/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.919123/full

Similar Items